Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2024 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 42nd...
November 27, 2023 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the...
November 03, 2023 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the...
November 01, 2023 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Third quarter 2023 total net revenue of $165.8 million, including quarterly BRIUMVI® net sales of $25.1 million in the United States, and license revenue of $140.0 million from the upfront payment...
October 30, 2023 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Wednesday, November 1, 2023, at 8:30 AM ET to discuss results...
October 12, 2023 11:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI®...
October 11, 2023 10:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b...
October 02, 2023 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from both the ULTIMATE I & II Phase 3...
September 22, 2023 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

NEW YORK, Sept. 22, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the...
September 07, 2023 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the...